Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.7950
-0.0100 (-1.24%)
Sep 9, 2026, 4:00 PM EDT - Market closed
Oncolytics Biotech Employees
Oncolytics Biotech had 29 employees as of December 31, 2025. The number of employees increased by 1 or 3.57% compared to the previous year.
Employees
29
Change (1Y)
1
Growth (1Y)
3.57%
Revenue / Employee
n/a
Profits / Employee
-$1,291,586
Market Cap
101.37M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | 1 | 3.57% |
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Adicet Bio | 102 |
| Fractyl Health | 100 |
| PolyPid | 75 |
| PMV Pharmaceuticals | 54 |
| RenovoRx | 17 |
| Atara Biotherapeutics | 10 |
| Coya Therapeutics | 8 |
ONCY News
- 21 days ago - Oncolytics price target lowered to $5 from $10 at H.C. Wainwright - TheFly
- 22 days ago - Oncolytics aligns with FDA on path for REO 033 expansion study - TheFly
- 22 days ago - Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer - GlobeNewsWire
- 4 weeks ago - Oncolytics Biotech Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Oncolytics announces FDA Fast Track designation for pelareorep - TheFly
- 7 weeks ago - Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer - GlobeNewsWire
- 1 month ago - Oncolytics provides clinical, regulatory update on REO 033 - TheFly
- 1 month ago - Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial - GlobeNewsWire